Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Tumor-specific antigens (TSAs) represent ideal targets for cancer immunotherapy, but few
have been identified thus far. We therefore developed a proteogenomic approach to enable …

Functional diversity of the highly polymorphic human leukocyte antigen class I (HLA-I) genes
underlies successful immunologic control of both infectious disease and cancer. The …

Immunotherapies are yielding effective treatments for several previously untreatable
cancers. Still, the identification of suitable antigens specific to the tumour that can be targets …

The use of vaccines have resulted in a remarkable improvement in global health. It has
saved several lives, reduced treatment costs and raised the quality of animal and human …

Proteomics, the study of all the proteins in biological systems, is becoming a data‐rich
science. Protein sequences and structures are comprehensively catalogued in online …

Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …